about
Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.Current Treatment of Chronic Lymphocytic Leukemia.Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 January 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Idelalisib for the treatment of non-Hodgkin lymphoma.
@en
Idelalisib for the treatment of non-Hodgkin lymphoma.
@nl
type
label
Idelalisib for the treatment of non-Hodgkin lymphoma.
@en
Idelalisib for the treatment of non-Hodgkin lymphoma.
@nl
prefLabel
Idelalisib for the treatment of non-Hodgkin lymphoma.
@en
Idelalisib for the treatment of non-Hodgkin lymphoma.
@nl
P2860
P1476
Idelalisib for the treatment of non-Hodgkin lymphoma
@en
P2093
Solomon A Graf
P2860
P304
P356
10.1517/14656566.2016.1135130
P407
P50
P577
2016-01-28T00:00:00Z